#NephrOdio podcasts 🎧
🚀 Half a million downloads !

💊 First-line treatment: RAAS blockade (#ACEi or #ARB).
Other drugs can be added depending on context:
• thiazide(-like) diuretics
• calcium channel blockers
• β-blockers
→ Adapted based on comorbidities, side effects, or tolvaptan use.

📚 The 2025 #KDIGO Guidelines recommend ambitious BP targets to manage hypertension in ADPKD:
🎯 ≤110/75 mmHg (HBPM) for adults <50 y with preserved renal function (G1–G2),
🎯 <120 mmHg systolic (office BP) in older adults, if tolerated.

🔬 Before kidney function declines, 2 disease-specific mechanisms drive early #hypertension in #ADPKD:
📍 Local ischemia due to kidney #cyst expansion → RAAS activation
📍 Loss of polycystin function in blood vessels → primary #endothelial dysfunction
→ This sets ADPKD apart from other forms of CKD

🫀 #Hypertension in autosomal dominant polycystic kidney disease: unique pathways, common consequences.
In #ADPKD, high blood pressure is often the first clinical sign and not just a complication of the kidney disease.
Actually its mechanisms differ markedly from other CKD-related hypertension... 🧵

Mmmmh, curious to see where ESH2023 recommends SBP<120

Just published in NDT : #SGLT2i for patients with #ADPKD – closing the evidence gap

With experts from 🇩🇪🇳🇱🇯🇵🇺🇸🇫🇷 we review:
✅ Rationale for SGLT2i in ADPKD
✅ Preclinical and observational evidence
✅ Potential disease-specific benefits and risks
✅ Ongoing/upcoming trials, incl. #DAPAPKD & #STOPPKD

Thanks Swapnil!
Here is the link to the #NephrOdio podcast evaluated in the study: open.spotify.com/show/2UBeBVb...

📍Pourquoi développe-t-on une #HTA ?

🫀 Vasoconstriction, rigidité vasculaire, hypervolémie, inflammation… L’HTA résulte généralement de plusieurs mécanismes intriqués 🔄

🎙️ Dans ce nouvel épisode de #NephrOdio, on vous décrypte ça en 6 min chrono !

📢 Écoutez ici 👉 open.spotify.com/episode/7CpB...

#NephrOdio, bien sûr 😉

Hi Swapnil, as you may know 2 large RCTs, DAPA-PKD & STOP-PKD have secured academic funding to evaluate the use of SGLT2i in ADPKD. They are set to launch in 2026.

Upon completion, both trials will combine their datasets in a pooled analysis, called FLOZIN-PKD. Hope you like the name 😉

🎙️ L’enregistrement de la saison 3 de #NephrOdio, dédiée à la #physiologie rénale, est en cours !

Après les saisons 1 (Items EDN) et 2 (ECOS), les #podcasts du #CUEN continuent sur leur dynamique ! 🚀

📅 Disponible en mars 2025 sur toutes les plateformes

🤔 Should most older people with BP 120–139 / 70–89 mmHg be treated, as suggested by #ESC 2024 #hypertension guideline ?

Interesting counterpoint here :
www.tandfonline.com/doi/full/10....

#BPROAD Graphical abstract #AHA24

Here are the main results of the #BROAD RCT.

Composite primary outcome (stroke, MI, treatment or hospitalization for HF, or CV death) ✅
Kidney outcomes ❌ (as usual in BP trials)

#AHA24